Which has preferable valuation & earnings, AVCT or 4BB?

4basebio has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 2,966.27 -£30.08M -£9.66 N/A 4basebio £1.69M 50.31 -£9.84M -£109.00 N/A

Is AVCT or 4BB more profitable?

4basebio has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. 4basebio's return on equity of -231.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Avacta Group -33,961.06% -2,929.47% -21.80% 4basebio N/A -231.29% -54.30%

Is 4BB or PRTC more profitable?

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% PureTech Health -2,355.32% -31.98% -13.39%

Does the media favor 4BB or PRTC?

In the previous week, 4basebio had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for 4basebio and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat 4basebio's score of -0.07 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4basebio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend HZD or 4BB?

4basebio has a consensus price target of GBX 1,400, indicating a potential upside of 154.55%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is HZD or 4BB more profitable?

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets Horizon Discovery Group plc (HZD.L) N/A N/A N/A 4basebio N/A -231.29% -54.30%

Do analysts prefer VRP or 4BB?

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 154.55%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Verona Pharma plc (VRP.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma plc (VRP.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is VRP or 4BB more profitable?

Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets Verona Pharma plc (VRP.L) N/A N/A N/A 4basebio N/A -231.29% -54.30%

Which has preferable valuation & earnings, 4BB or BTG?

BTG has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4basebio £1.69M 50.31 -£9.84M -£109.00 N/A BTG £159.40M 1.21 N/A £6.00 20.00

Is 4BB or BTG more profitable?

BTG's return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% BTG N/A N/A N/A

Does the media refer more to 4BB or BTG?

In the previous week, BTG had 2 more articles in the media than 4basebio. MarketBeat recorded 6 mentions for BTG and 4 mentions for 4basebio. BTG's average media sentiment score of 0.02 beat 4basebio's score of -0.07 indicating that BTG is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4basebio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BTG 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

4basebio (4BB) Competitors

GBX 550 +25.00 (+4.76%)

As of 06/19/2026 11:49 AM Eastern

Compare

4BB vs. AVCT, PRTC, HZD, VRP, and BTG

Should you buy 4basebio stock or one of its competitors? MarketBeat compares 4basebio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4basebio include Avacta Group (AVCT), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), and BTG (BTG). These companies are all part of the "biotechnology" industry.

How does 4basebio compare to Avacta Group?

Avacta Group (LON:AVCT) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

In the previous week, 4basebio had 4 more articles in the media than Avacta Group. MarketBeat recorded 4 mentions for 4basebio and 0 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.00 beat 4basebio's score of -0.07 indicating that Avacta Group is being referred to more favorably in the media.

Company	Overall Sentiment
Avacta Group	Neutral
4basebio	Neutral

4basebio has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. 4basebio's return on equity of -231.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
4basebio	N/A	-231.29%	-54.30%

2.9% of Avacta Group shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 49.1% of Avacta Group shares are owned by insiders. Comparatively, 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Avacta Group presently has a consensus price target of GBX 99, indicating a potential upside of 34.42%. 4basebio has a consensus price target of GBX 1,400, indicating a potential upside of 154.55%. Given 4basebio's higher probable upside, analysts clearly believe 4basebio is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

4basebio has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,966.27	-£30.08M	-£9.66	N/A
4basebio	£1.69M	50.31	-£9.84M	-£109.00	N/A

Summary

Avacta Group and 4basebio tied by winning 7 of the 14 factors compared between the two stocks.

How does 4basebio compare to PureTech Health?

4basebio (LON:4BB) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.811, indicating that its share price is 19% less volatile than the broader market.

0.9% of 4basebio shares are held by institutional investors. Comparatively, 34.0% of PureTech Health shares are held by institutional investors. 12.1% of 4basebio shares are held by insiders. Comparatively, 13.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

4basebio has higher earnings, but lower revenue than PureTech Health. 4basebio is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	50.31	-£9.84M	-£109.00	N/A
PureTech Health	£4.66M	68.65	-£91.86M	-£46.00	N/A

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 154.55%. PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 286.61%. Given PureTech Health's higher possible upside, analysts clearly believe PureTech Health is more favorable than 4basebio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, 4basebio had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for 4basebio and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat 4basebio's score of -0.07 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4basebio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Summary

PureTech Health beats 4basebio on 10 of the 14 factors compared between the two stocks.

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

4basebio has a consensus price target of GBX 1,400, indicating a potential upside of 154.55%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, 4basebio had 4 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 4 mentions for 4basebio and 0 mentions for Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 beat 4basebio's score of -0.07 indicating that Horizon Discovery Group plc (HZD.L) is being referred to more favorably in the media.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
4basebio	Neutral

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
4basebio	£1.69M	50.31	-£9.84M	-£109.00	N/A

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

4basebio beats Horizon Discovery Group plc (HZD.L) on 7 of the 12 factors compared between the two stocks.

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L) (LON:VRP) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, 4basebio had 4 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 4 mentions for 4basebio and 0 mentions for Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L)'s average media sentiment score of 0.00 beat 4basebio's score of -0.07 indicating that Verona Pharma plc (VRP.L) is being referred to more favorably in the media.

Company	Overall Sentiment
Verona Pharma plc (VRP.L)	Neutral
4basebio	Neutral

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 154.55%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Verona Pharma plc (VRP.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma plc (VRP.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

0.9% of 4basebio shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma plc (VRP.L)	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

Verona Pharma plc (VRP.L) has higher earnings, but lower revenue than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A
4basebio	£1.69M	50.31	-£9.84M	-£109.00	N/A

Summary

4basebio beats Verona Pharma plc (VRP.L) on 7 of the 12 factors compared between the two stocks.

How does 4basebio compare to BTG?

4basebio (LON:4BB) and BTG (LON:BTG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

0.9% of 4basebio shares are held by institutional investors. Comparatively, 19.7% of BTG shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 19.7% of BTG shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BTG had 2 more articles in the media than 4basebio. MarketBeat recorded 6 mentions for BTG and 4 mentions for 4basebio. BTG's average media sentiment score of 0.02 beat 4basebio's score of -0.07 indicating that BTG is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4basebio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BTG	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 154.55%. BTG has a consensus target price of GBX 160, suggesting a potential upside of 33.33%. Given 4basebio's higher possible upside, analysts plainly believe 4basebio is more favorable than BTG.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

BTG has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	50.31	-£9.84M	-£109.00	N/A
BTG	£159.40M	1.21	N/A	£6.00	20.00

BTG's return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
BTG	N/A	N/A	N/A

Summary

BTG beats 4basebio on 10 of the 12 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

4BB vs. The Competition

Export

Metric	4basebio	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£85.17M	£381.57M	£6.43B	£2.88B
Dividend Yield	N/A	3.86%	2.68%	6.15%
P/E Ratio	-5.05	3.12	20.90	366.85
Price / Sales	50.31	6,861.77	529.30	86,444.11
Price / Cash	16.08	13.13	27.92	27.85
Price / Book	-13.41	92.26	10.81	8.01
Net Income	-£9.84M	-£96.07M	£3.57B	£5.89B
7 Day Performance	4.76%	0.88%	0.72%	0.07%
1 Month Performance	7.21%	-0.66%	0.41%	0.93%
1 Year Performance	-45.54%	54.58%	29.34%	72.13%

4basebio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
4BB 4basebio	2.5369 of 5 stars	GBX 550 +4.8%	GBX 1,400 +154.5%	-45.5%	£85.17M	£1.69M	N/A	101
AVCT Avacta Group	N/A	GBX 70.78 +3.3%	GBX 99 +39.9%	+126.6%	£311.75M	£113K	N/A	120	Gap Up
PRTC PureTech Health	1.4923 of 5 stars	GBX 131.20 +2.8%	GBX 508 +287.2%	+1.7%	£310.60M	£4.66M	N/A	300	Positive News
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:4BB) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4basebio (4BB) Competitors

4BB vs. AVCT, PRTC, HZD, VRP, and BTG

How does 4basebio compare to Avacta Group?

Summary

How does 4basebio compare to PureTech Health?

Summary

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Summary

How does 4basebio compare to BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4basebio (4BB) Competitors

4BB vs. AVCT, PRTC, HZD, VRP, and BTG

How does 4basebio compare to Avacta Group?

Does the media refer more to AVCT or 4BB?

Is AVCT or 4BB more profitable?

Do insiders & institutionals have more ownership in AVCT or 4BB?

Which has more volatility & risk, AVCT or 4BB?

Do analysts rate AVCT or 4BB?

Which has preferable valuation & earnings, AVCT or 4BB?

Summary

How does 4basebio compare to PureTech Health?

Which has more volatility & risk, 4BB or PRTC?

Do institutionals & insiders have more ownership in 4BB or PRTC?

Which has higher valuation & earnings, 4BB or PRTC?

Do analysts prefer 4BB or PRTC?

Does the media favor 4BB or PRTC?

Is 4BB or PRTC more profitable?

Summary

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Do analysts recommend HZD or 4BB?

Does the media prefer HZD or 4BB?

Is HZD or 4BB more profitable?

Which has stronger valuation and earnings, HZD or 4BB?

Do insiders & institutionals believe in HZD or 4BB?

Summary

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Does the media refer more to VRP or 4BB?

Do analysts prefer VRP or 4BB?

Do institutionals and insiders believe in VRP or 4BB?

Is VRP or 4BB more profitable?

Which has preferable valuation and earnings, VRP or 4BB?

Summary

How does 4basebio compare to BTG?

Do insiders and institutionals have more ownership in 4BB or BTG?

Does the media refer more to 4BB or BTG?

Do analysts prefer 4BB or BTG?

Which has preferable valuation & earnings, 4BB or BTG?

Is 4BB or BTG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools